Alzheon, headquartered in United States, remains privately held in the biopharmaceutical space. Its most recent disclosed valuation is $1.3B. The stock is not listed on any public market.
One company valuation: $1.3B.
Thornapple River CapitalNNational Institute on AgingHHCL CapitalAlzheon is a clinical-stage biopharmaceutical company developing medicines for Alzheimer's disease and other neurological and psychiatric disorders. Its lead candidate, valiltramiprosate (ALZ-801), is an oral prodrug that targets neurotoxic soluble amyloid oligomers and received Fast Track designation from the FDA in 2017.
Martin Tolar founded Alzheon in July 2013, and the company is based in Framingham, Massachusetts. Its Phase 3 program focuses on patients carrying two copies of the APOE4 gene, who face up to 20 times the risk of developing Alzheimer's disease.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Alzheon.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Alzheon availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Alzheon included.
Lead investors for each round are in the funding timeline.
The closest biopharmaceutical peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Alzheon is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
